Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Posts Record High H1 Earnings for 6th Consecutive Year Driven by Opdivo
November 2, 2023
- Shionogi, Apnimed to Launch Joint Venture to Develop Sleep Apnea Drugs
November 2, 2023
- Astellas Squeaks Out Sales Rise as FX, Mainstay Growth Offset Generic Hit
November 2, 2023
- Mitsubishi Tanabe’s April-September Sales Up 8% on Radicava
November 2, 2023
- Kyowa Kirin Drops Acoalan’s Preeclampsia Program after PIII Miss
November 2, 2023
- Otsuka Ups 2023 Full-Year Sales Forecast on Bullish Global Brands
November 2, 2023
- Shionogi, Mochida Form Sales Tie-Up for Daridorexant in Japan
November 2, 2023
- Daiichi Sankyo to Merge 2 Subsidiaries to Enhance ADC Production
November 1, 2023
- Otsuka Files Rexulti for Alzheimer’s Associated Agitation in Japan
November 1, 2023
- Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
- Otsuka Calls Off PIII Bipolar Trial for SEP-4199 on Stalled Recruitment
November 1, 2023
- Daiichi Sankyo’s H1 Sales Jump 19.5% on Robust Global Products
November 1, 2023
- Idorsia Files Insomnia Med Daridorexant in Japan: Sosei, Mochida
November 1, 2023
- Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
November 1, 2023
- 301 Employees Apply for Shionogi’s Voluntary Buyout Program
November 1, 2023
- VLP Therapeutics Eyes Japan Filing of Next-Gen mRNA Vaccine in Mid-2024: CEO
October 31, 2023
- BIKEN Files Updated Version of Measles-Rubella Vaccine Mearubik
October 31, 2023
- Hyftor Now Available in EU, UK: Nobelpharma
October 31, 2023
- Nippon Kayaku Gets Japan Commercial Rights to Anheart’s ROS1 Inhibitor
October 31, 2023
- Otsuka’s ADHD Med Hits Mark in PIII Pediatric Trials in US
October 30, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…